organization · Reporting owner

Logos Global Management LP

Disclosed activity across 3 companies

Tapewire entity: 117891
SEC CIK: 0001792126

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Eledon Pharmaceuticals, Inc.NVUS · Entity 6160	10% owner	October 30, 2020	November 06, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Eledon Pharmaceuticals, Inc.

Report date October 30, 2020 · Filed November 06, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Notes 1 and 2	224,071	Last balance in matching sequence After 2020-10-30 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 9 source rows Row 1 · 2020-10-30 · Purchase · Acquired 5,000 · Balance 150,000 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 2 · 2020-10-30 · Purchase · Acquired 31,000 · Balance 181,000 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 3 · 2020-10-30 · Purchase · Acquired 4,000 · Balance 185,000 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 4 · 2020-10-30 · Purchase · Acquired 15,000 · Balance 200,000 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 5 · 2020-10-30 · Sale · Disposed 12,942 · Balance 187,058 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 6 · 2020-10-30 · Purchase · Acquired 12,942 · Balance 200,000 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 7 · 2020-10-30 · Sale · Disposed 27 · Balance 199,973 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 8 · 2020-10-30 · Purchase · Acquired 15,000 · Balance 214,973 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 9 · 2020-10-30 · Purchase · Acquired 9,098 · Balance 224,071 F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.

F2: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Section 16 reporting ended · disclosed 2020-09-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	1,504,392	Last balance in matching sequence After 2020-09-21 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-09-21 · Conversion · Acquired 804,392 · Balance 804,392 F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 2 · 2020-09-21 · Purchase · Acquired 700,000 · Balance 1,504,392 F2: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2020-09-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-09-21 · Conversion · Disposed 2,668,089 · Balance 0 F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.

F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Verve Therapeutics, Inc.

Report date June 21, 2021 · Filed June 22, 2021

Section 16 reporting ended · disclosed 2021-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	443,265	Reported balance After 2021-06-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-06-21 · Conversion · Acquired 443,265 · Balance 443,265 F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2: The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	370,000	Reported balance After 2021-06-21 transaction · row 2 1 source row Row 2 · 2021-06-21 · Purchase · Acquired 370,000 · Balance 370,000
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2021-06-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-21 · Conversion · Disposed 4,104,416 · Balance 0 F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2: The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.

F2: The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.

F3: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 21, 2021 Filed Jun 22, 2021 17:21 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	ConversionSeries B Preferred Stock · Derivative	4,104,416	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-025313 · doc4.xml · derivative · entry 3 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 443,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
June 21, 2021 Filed Jun 22, 2021 17:21 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	PurchaseCommon Stock	370,000	$19.00	$7,030,000.00	Disclosure SEC source: 0000899243-21-025313 · doc4.xml · nonDerivative · entry 2 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,000 Read SEC document
June 21, 2021 Filed Jun 22, 2021 17:21 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	ConversionCommon Stock	443,265	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-025313 · doc4.xml · nonDerivative · entry 1 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 443,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The reporting persons are Logos Opportunities Fund II, LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William is the controlling person of LGM and Logos GP and Dr. William and Dr. Walmsley are the managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William as controlling person of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	9,098	$25.55	$232,460.27	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 9 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 224,071 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	15,000	$26.17	$392,610.00	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 8 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 214,973 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	SaleCommon Stock	27	$27.02	$729.54	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 7 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 199,973 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	12,942	$25.88	$334,926.02	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 6 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 200,000 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	SaleCommon Stock	12,942	$26.64	$344,829.24	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 5 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 187,058 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	15,000	$26.48	$397,236.00	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 4 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 200,000 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	4,000	$25.97	$103,892.00	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 3 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 185,000 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	31,000	$24.53	$760,426.90	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 2 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 181,000 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
October 30, 2020 Filed Nov 6, 2020 23:46 UTC	Eledon Pharmaceuticals, Inc. NVUS · Entity 6160	PurchaseCommon Stock	5,000	$24.03	$120,162.50	Disclosure SEC source: 0001567619-20-018886 · doc1.xml · nonDerivative · entry 1 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 150,000 F1 · ownership.nature: The reporting persons are Logos Global Management LP ("LGM"), Logos Global Master Fund LP (the "Fund"), and Logos GP LLC ("Fund GP"). LGM is the investment adviser of private funds, including the Fund. Fund GP is the general partner of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F2 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund and by Fund GP as general partner of the Fund. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 21, 2020 Filed Sep 23, 2020 23:09 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionSeries B Preferred Stock · Derivative	2,668,089	$0.00	$0.00	Disclosure SEC source: 0000899243-20-026189 · doc4.xml · derivative · entry 3 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 804,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 21, 2020 Filed Sep 23, 2020 23:09 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	PurchaseCommon Stock	700,000	$19.00	$13,300,000.00	Disclosure SEC source: 0000899243-20-026189 · doc4.xml · nonDerivative · entry 2 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,504,392 F2 · ownership.nature: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
September 21, 2020 Filed Sep 23, 2020 23:09 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	ConversionCommon Stock	804,392	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-026189 · doc4.xml · nonDerivative · entry 1 Logos Global Management LP · CIK 0001792126 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 804,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. F3 · ownership.nature: The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.